Cargando…
Hope for primary cardiovascular prevention with the HOPE (Heart Outcomes Prevention Evaluation)-3 trial findings
The HOPE-3 investigators enrolled 12,705 intermediate-risk participants in 21 countries in a 2-by-2 factorial trial. Subjects were randomized to receive a fixed dose of rosuvastatin or placebo, candesartan plus hydrochlorothiazide daily or placebo, and a third group received combination of antihyper...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Magdi Yacoub Heart Foundation
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584400/ https://www.ncbi.nlm.nih.gov/pubmed/31463302 http://dx.doi.org/10.21542/gcsp.2016.13 |